.svg)
Bring the immune system one step ahead of cancer
Off-the-shelf platform advancing next-generation in vivo immunotherapies to unlock immune response against solid tumors
.png)
Redefining immuno-oncology through novel modalities
Our focus: solid tumors
Fast growing needs, insufficient solutions
of patient face therapeutic failure
every year worldwide
The challenge
Cancer is a moving, heterogeneous & invisible target
Colorectal cancer (CRC) is the 2nd cause of cancer mortality worldwide,
and is defined by heterogeneity, plasticity and treatment resistances
of patients have no other solution than outdated chemotherapies
of patients survive after 5-year of treatment
For these patients: the immune system, natural body’s defenser, is blinded
New therapeutic strategies are needed to restore anti-tumor immune response and capture cancer heterogeneity
Our solution:
Next-generation in vivo
immunotherapies
Inspired by patients,
driven by science
Mimicking cancer to make it visible
We model solid tumors complexity using off-the-shelf cell lines, stimulated to reveal cancer-related proteins and validated by proteogenomic and predictive model.
These cells are then tagged with an immune flare (hapten), and inactivated into ghost cells to safely educate the immune system, to target evolving cancer cells and eradicate cancer.
From vision to execution
Invested since 2020
Clinical candidates advancing toward IND filing by 2027
Clinical sites open in 2027
Phase I/II for colorectal cancer patients in 1L
(US expansion planned)
patients treatable per batch
thanks to our standardized & scalable platform
Eligible patients by 2029
Latest news and research
